Quantcast

Latest Postherpetic neuralgia Stories

2014-06-03 04:21:17

MELBOURNE, Australia and STAMFORD, Connecticut, June 3, 2014 /PRNewswire/ -- Spinifex Pharmaceuticals, a pain drug development company, today announces that it has appointed Dr Ronald Marcus as Chief Medical Officer. Dr Marcus will be responsible for driving the development of Spinifex's lead candidate EMA401 and the Company's pre-clinical pipeline. He takes up his position immediately. EMA401 is a novel angiotensin II type 2 (AT2) receptor antagonist being developed as...

2014-05-27 16:25:31

NEWARK, Calif., May 27, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City. The presentation at the Jefferies conference is scheduled for 11:00 am ET (8:00 am PT) on Tuesday June 3, 2014. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for...

2014-05-27 04:21:49

MELBOURNE, Australia, May 27, 2014 /PRNewswire/ -- Expanded SAB will oversee development of EMA401, Company's lead program for treating chronic pain Spinifex Pharmaceuticals, a pain drug development company, today announces that three internationally acclaimed scientists in chronic pain research have joined the Company's Scientific Advisory Board (SAB). Their core research areas include understanding the basis for pain...

2014-05-22 23:15:44

“Those with herpes zoster had a higher incidence of developing major depression,” according to a study published on May 7, 2014 in Psychosomatic Medicine (1).” polyDNA reviews the study and recommends that individuals take Gene-Eden-Vir and Novirin against the latent herpes zoster virus. Rochester, NY (PRWEB) May 22, 2014 The presence of the varicella zoster virus (VZV or herpes zoster virus), which causes chickenpox and shingles, has also been linked to the development of major...

2014-05-19 08:29:19

Scilex has commenced with its pivotal bioequivalence study of Ztilido versus Lidoderm® in accordance with FDA recommendations to support approval of Ztilido submitted as a 505(b)(2) NDA MALVERN, Pa., May 19, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain, announced today that it has initiated a pivotal pharmacokinetic (PK) study of its investigational...

2014-05-14 23:13:17

“Some natural treatments may be effective in easing the pain and discomfort of shingles,” according to an article published on Healthline.com on October 28, 2013. polyDNA reviews the article and recommends Gene-Eden-VIR and Novirin, the most effective natural antiviral products on the market, to help the immune system target the latent Varicella Zoster Virus that causes Shingles. Rochester, NY (PRWEB) May 14, 2014 polyDNA’s latest May 2014 survey found that 78% of participants who...

2014-05-09 16:24:36

NEWARK, Calif., May 9, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at two upcoming investor conferences: Bank of America Merrill Lynch Healthcare Conference in Las Vegas Nevada on Thursday May 15 at 11:00 am Eastern Time (8:00 am Pacific Time). UBS Global Healthcare Conference in New York City on Monday May 19 at 9:00 am Eastern Time (6:00 am Pacific Time). The presentations will be webcast, and the webcasts can be accessed via the...

2014-05-05 08:30:14

Mr. Sendrow Joins Pharmaceuticals Product Development and Regulatory Expert Eric Floyd, Ph.D. on the Board MALVERN, Pa., May 5, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced the appointment of finance and accounting veteran Jerrold Sendrow to the Company's board of directors. Mr. Sendrow brings to SCILEX twenty-eight years of experience in finance and...

2014-04-30 16:30:40

NEWARK, Calif., April 30, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2014 financial results after the market closes on Thursday, May 8, 2014. The Company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm Pacific time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a...

2014-04-14 12:33:34

NEWARK, Calif., April 14, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into settlement agreements with two of the three defendants involved in Depomed's ongoing patent infringement litigation against filers of Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Depomed's Gralise(®) (gabapentin) 300 mg and 600 mg tablets. The settlements permit the defendants to begin selling generic versions of Gralise on...


Latest Postherpetic neuralgia Reference Libraries

69_7b87211f9314eacab994d465558a3a1b
2011-01-24 12:56:26

Herpes zoster (or zoster), is known as shingles or zona and is a viral disease characterized by painful skin rash with blisters in a limited area on one side of the body. Initial infection causes chickenpox. Once chickenpox is over the virus remains in the body and can cause shingles. It can become latent in the nerve cell bodies and sometimes in the dorsal root, cranial nerve, or autonomic ganglion. Years after initial infection, another breakout can cause a painful rash. The rash usually...

More Articles (1 articles) »
Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'